Inherited Retinal Diseases

Latest News

ViGeneron doses first patient in Phase 1b clinical trial of VG901 for the intravitreal treatment of RP
ViGeneron doses first patient in Phase 1b clinical trial of VG901 for the intravitreal treatment of RP

April 11th 2024

According to the company, VG901 is designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in patients diagnosed with retinitis pigmentosa. It has been granted Orphan Drug Designation by FDA.

Ocugen, Inc. announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
Ocugen, Inc. announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial

April 8th 2024

Belite Bio completes submission to PMDA to initiate Dragon II trial of Tinlarebant for the treatment of adolescent Stargardt disease in Japan
Belite Bio completes submission to PMDA to initiate Dragon II trial of Tinlarebant for the treatment of adolescent Stargardt disease in Japan

March 28th 2024

BlueRock Therapeutics and Foundation Fighting Blindness collaborate to add new cohort to Uni-Rare study evaluating inherited retinal diseases
BlueRock Therapeutics and Foundation Fighting Blindness collaborate to add new cohort to Uni-Rare study evaluating inherited retinal diseases

March 28th 2024

Opus Genetics completes dosing of the first cohort in Phase 1/2 trial evaluating the subretinal delivery of OPGx-LCA5
Opus Genetics completes dosing of the first cohort in Phase 1/2 trial evaluating the subretinal delivery of OPGx-LCA5

March 27th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.